Skip to main content

MDS 2017

  • Day 1
  • Day 2
  • Day 3
  • Day 4
  • Agenda

Updated results from Phase 2 Study of Guadecitabine for Patients with Previously Untreated Int-2 or High Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia?

May 5, 2017August 13, 2017 liorco70

http://d22fjzb79sfamb.cloudfront.net/MDS2017/fri/1200%20-%201330/Fri%201315.mp4

G. Montalban-Bravo (USA)

Post navigation

Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)
Selection and Timing of Allogeneic Hematopoietic Stem Cell transplantation in MDS

Day 3

Plenary Session: SINGULAR SUBTYPES OF MDS

  • 08:30 Benjamin Levine Ebert (USA)
  • 08:50 Ghulam J. Mufti (United Kingdom)
  • 09:10 Charlotte Niemeyer (Germany)
  • 09:45 T. Radivoyevitch (USA)

Plenary Session: THERAPY-1: CURRENT OPTIONS

  • 10:30 Pierre Fenaux (France)
  • 10:50 Aristoteles Giagounidis (Germany)
  • 11:10 Mikkael Sekeres (USA)
  • 11:30 P. Fenaux (France)
  • 11:45 M. Dickinson (Australia)

Plenary Session: THERAPY-2: NEW DEVELOPMENTS

  • 12:00 Lionel Ades (France)
  • 12:20 Guillermo Garcia-Manero (USA)
  • 13:00 E.M. Stein (USA)
  • 13:15 G. Montalban-Bravo (USA)

Plenary Session: THERAPY-3: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

  • 15:00 Theo De Witte (The Netherlands)
  • 15:20 Charles Craddock (United Kingdom)
  • 15:40 David Valcarcel (Spain)
  • 16:00 H. Itonaga (Japan)
  • 16:15 J.C. Caballero Berrocal (Spain)
sparkling Theme by Colorlib Powered by WordPress